Verimatrix and AgileTV Partner to Secure Fast-Growing TVaaS Solution
2.4.2025 17:45:00 CEST | Business Wire | Press Release
Regulatory News:
Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced expanded collaboration with Bilbao, Spain-based AgileTV (BME: AGIL.MC) to provide the latest content security innovations for AgileTV’s cloud-based TV-as-a-Service (TVaaS) Entertainment Hub, OTT and video delivery solutions designed to empower telcos, ISPs and media companies.
By partnering with Verimatrix, which offers its vast portfolio of proven video security solutions including VCAS, Multi-DRM, Counterspy (watermarking) and DVB ReAccess, AgileTV gains a significantly streamlined path toward providing the most recent and reliable protection options to its global customer base. Through the collaboration, Verimatrix streamlines that protection process for AgileTV, enabling it to offer customers the ability to:
- Simplify the transition from legacy DVB and IPTV operations into hybrid or fully-fledged “nextgen” OTT service powered by AgileTV, thanks to the VCAS and DVB ReAccess capabilities to replace existing security providers.
- Confidently provides both existing and future needs surrounding highly-valuable premium content that demands specific protection, establishing Agile TVaaS as a vehicle to securely distribute and monetize content.
- Offer peace of mind for customers that prefer long-time industry innovators with a record of success in the content delivery network space.
“Verimatrix is extremely pleased to further its collaboration with AgileTV, as it underscores our ability to efficiently arm such an innovative and successful TVaaS provider with the needed content security technologies that match today’s ever-evolving video content delivery options,” said Carlo Stramaglia, Head of Anti-Piracy Business at Verimatrix. “In the end, the repeatedly proven value we bring is to allow a partner such as AgileTV to focus on its core value proposition as TVaaS offering, while we closely work alongside them to ensure that security is strong and seamless. Consistently streamlining this content protection process is what we’re proud to be known for in the industry. That’s what makes Verimatrix a true business enabler for companies such as AgileTV.”
“AgileTV is proud to be recognized as a leader in the TVaaS space, offering solutions that combine a comprehensive and innovative TV technology suite with our best-in-class Operational Excellence Model”, said Ruben Senor-Megias, Chief Sales officer at AgileTV. “Foundational to our product proposition is how we leverage on a “best-of-breed” partner ecosystem. In this sense, we are proud to announce our joint approach with Verimatrix, a leading Security Provider, which is key to our relentless focus on Content Security and revenue protection for our Content owners. Besides the existing collaboration for M-DRM, we believe Verimatrix VCAS and DVB ReAccess solutions are enablers to support customer transitions from legacy distribution solutions to advanced OTT solutions, thus improving the service for their customer base”.
In 2020, Verimatrix and AgileTV announced their collaboration to include Verimatrix Multi-DRM technologies within AgileTV offerings.
About Agile Technologies
AgileTV is a technology company providing end-to-end solutions for pay TV services over the Internet. Its customers include telecom providers, content creators, broadcasters and multimedia content management companies. The portfolio spans fully managed TV services, SaaS applications and infrastructure platforms, delivering innovative, cost-effective and scalable solutions for the TV business. With more than 300 professionals in 15 countries, AgileTV has over 20 years of experience, serving 120+ global clients and reaching more than 50 million households worldwide through its technologies. Headquartered in Bilbao, the company centralizes R&D&I activities, collaborating with international partners to revolutionize the television experience. Founded in 2007, AgileTV is a brand of Agile Content, listed on the BME Growth market since 2015. Visit www.agiletv.com.
About Verimatrix
Verimatrix (Euronext Paris: VMX, FR0010291245) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure premium movies, live streaming sports, sensitive financial and healthcare data, mission-critical mobile applications, and much more. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250327069574/en/
Contacts
Verimatrix Investor:
Jean-François Labadie, Chief Financial Officer
finance@verimatrix.com
SEITOSEI.ACTIFIN
Michael Scholze
Michael.scholze@seitosei-actifin.com
Verimatrix Media:
Matthew Zintel
matthew.zintel@zintelpr.com
AgileTV Media:
Raquel Martínez Alfonso
raquel.martinez@agiletv.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom